Biologics: Targets & Therapy
About Dovepress

Open access peer-reviewed scientific and medical journals.
Open Access

Dove Medical Press is now a member of the Open Access Initiative
An Author's Guide
A guide to help authors get their paper published.
Advocacy

Support Open Access and Dove Press
Reprints

Promotional Article Monitoring - further details
Favored Author Program

Real benefits for authors, including fast-track processing of papers.

Biologics: Targets & Therapy

Editor in Chief Professor Doris Mangiaracina Benbrook

Re-defining outcomes and re-evaluating remission in inflammatory bowel disease: Assessing key evidence
Laurence J Egan, Simon M Everett, Paul Rutgeerts

Testimonials
"... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University
Journal Indexing
See where all the Dove Press journals are indexed

Favored Author Program

We offer real benefits to our authors, including fast-track processing of papers.
Award Nominations Open

Nominations are now open for International Journal of Nanomedicine (IJN) Early Career Scientist Award, International Journal of Nanomedicine (IJN) Distinguished Scientist Award
Call For Submissions

Submit Original Research Article, Review, Case Report, or Rapid Communication in Biologics: Targets & Therapy
About Dovepress

Dove Medical Press Ltd is a privately held company specializing in the publication of Open Access peer-reviewed journals across the broad spectrum